Insider Sabba Files to Sell Ligand Pharma Shares

TL;DR

**Insider Sabba is selling Ligand Pharma shares, watch for potential stock price impact.**

AI Summary

Stephen L. Sabba, a reporting person, has filed a Form 144 indicating a proposed sale of securities in Ligand Pharmaceuticals Inc. (CIK: 0000886163). This filing, dated March 23, 2026, signals that an insider intends to sell shares, which could be interpreted by investors as a lack of confidence in the company's future prospects or simply a personal liquidity event. For current or prospective shareholders, this matters because significant insider selling can sometimes precede a decline in stock price, suggesting it's worth monitoring the actual sale and its impact.

Why It Matters

Insider selling can signal to the market that those with the most intimate knowledge of a company believe its stock may be fully valued or that they need personal liquidity, potentially impacting investor sentiment and stock price.

Risk Assessment

Risk Level: medium — Insider selling introduces uncertainty and can negatively influence investor perception, but the actual impact depends on the size and reason for the sale.

Analyst Insight

A smart investor would monitor the actual sale of shares by Stephen L. Sabba and observe the market's reaction to determine if this insider selling signals a broader negative sentiment or is merely a personal financial decision, potentially waiting for a clearer trend before making significant investment changes in Ligand Pharmaceuticals Inc.

Key Players & Entities

• Sabba Stephen L (person) — Reporting person proposing to sell securities
• LIGAND PHARMACEUTICALS INC (company) — Subject company whose securities are being sold
• 0001442372 (person) — CIK for Sabba Stephen L
• 0000886163 (company) — CIK for LIGAND PHARMACEUTICALS INC
• 2026-03-23 (date) — Filing Date

Forward-Looking Statements

• The stock price of Ligand Pharmaceuticals Inc. may experience downward pressure following the public disclosure of insider selling. (LIGAND PHARMACEUTICALS INC) — medium confidence, target: Within 3 months of 2026-03-23

FAQ

Filing Documents

• primary_doc.html (144)
• primary_doc.xml (144) — 4KB
• 0001950047-26-002891.txt ( ) — 5KB

From the Filing

Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 FORM 144 144: Filer Information Is this a LIVE or TEST Filing? LIVE TEST Submission Contact Information Name Phone E-Mail Address 144: Issuer Information Name of Issuer LIGAND PHARMACEUTICALS INCORPORATED Address of Issuer 555 Heritage Drive, Suite 200 Jupiter FLORIDA 33458 Phone (858) 550-7500 Name of Person for Whose Account the Securities are To Be Sold STEPHEN L. SABBA See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice. Relationship to Issuer Director 144: Securities Information Title of the Class of Securities To Be Sold Name and Address of the Broker Number of Shares or Other Units To Be Sold Aggregate Market Value Number of Shares or Other Units Outstanding Approximate Date of Sale Name the Securities Exchange Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York � NY � 10004 1000 207872.70 19941141 03/23/2026 NASDAQ Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor: 144: Securities To Be Sold Title of the Class Date you Acquired Nature of Acquisition Transaction Name of Person from Whom Acquired Is this a Gift? Date Donor Acquired Amount of Securities Acquired Date of Payment Nature of Payment * Common 03/05/2024 Exercised Shares Issuer 1000 03/05/2024 Cash * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid. Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold. 144: Securities Sold During The Past 3 Months Name and Address of Seller Title of Securities Sold Date of Sale Amount of Securities Sold Gross Proceeds STEPHEN L. SABBA 555 Heritage Drive, Suite 200 Jupiter � FL � 33458 Common 03/03/2026 2034 409851.00 144: Remarks and Signature Remarks Date of Notice 03/23/2026 ATTENTION: The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature /s/ Stephen L Sabba ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

View Full Filing

View this 144 filing on SEC EDGAR